Hospira Announces Plans to Integrate Symbiq(R) and EndoTool(R) Technologies

-- Prototype of the Innovative Combined Technology on Demonstration at AACN
Expo --

LAKE FOREST, Ill., May 19 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP),
a leading global specialty pharmaceutical and medication delivery company,
today announced the coming integration of its clinician-friendly Symbiq(R)
smart infusion pump and industry-leading EndoTool(R) glucose management
software. A prototype of this technologically advanced combination system is
being demonstrated at the American Association of Critical Care Nurses (AACN)
National Teaching Institute & Critical Care Exposition in New Orleans through
May 21.

"Unveiling the integrated Symbiq and EndoTool development effort illustrates
Hospira's commitment to providing cutting-edge medication delivery technology,
and ensuring compatibility between and integration of important hospital
technologies," said Philip Settimi, M.D., vice president, Global Marketing,
Global Devices, Hospira.

As a leading provider of advanced medication delivery systems, Hospira offers
hospitals and health institutions innovative solutions to improve clinician
efficiency and patient safety. The Symbiq infusion system, which helps prevent
medication errors, and the EndoTool glucose management system, a
clinical-decision support tool designed to aid workflow, are novel
technologies created with clinician input throughout the development process
to ensure maximum usability. The AACN Expo attendees will be able to provide
feedback regarding the integrated Symbiq/EndoTool system.

The Symbiq infusion system is a highly advanced, easy-to-use device with
several clinician-friendly features to help improve workflow and decrease
medication errors. An estimated 1.5 million medication errors occur annually,
with 400,000 preventable drug-related injuries occurring in hospitals (1).
With Hospira MedNet(R) safety software built into the device, Symbiq was the
first general infusion system designed to provide additional medication-error
protection by ensuring compliance with safety software. Symbiq requires users
to select a drug library entry from the safety software for all drug delivery
programs. With its innovative, award-winning human factors design, Symbiq also
incorporates an intuitive layout and a large LCD touch screen to help minimize
pump programming errors.

EndoTool is a highly sophisticated glucose management system designed to
improve the safety and quality of care, as related to the treatment of
hyperglycemia (high blood glucose). It calculates the dose of intravenous
(I.V.) insulin needed to effectively control blood glucose levels. EndoTool is
a 510(k) approved system. It is a dynamic and adaptive software, which
identifies individual patient responses to I.V. insulin to help manage current
and predict future dosage levels. Replacing the traditional paper-based system
used to manage insulin treatment, EndoTool helps clinicians maintain the
appropriate precision to manage blood glucose levels in a variety of hospital
settings. Overly aggressive insulin therapy can increase the risk of
hypoglycemia (low blood glucose), an independent risk factor for mortality
(2)(3). EndoTool software can operate on a hospital's existing computer
system, and is currently available for use on stand-alone personal computers
or in bedside terminal environments.

Hospira is targeting a 510(k) submission to the U.S. Food and Drug
Administration (FDA) for the integrated Symbiq/EndoTool system by the end of
the year.

About Hospira
Hospira, Inc. is a global specialty pharmaceutical and medication delivery
company dedicated to Advancing Wellness(TM). As the world leader in specialty
generic injectable pharmaceuticals, Hospira offers one of the broadest
portfolios of generic acute-care and oncology injectables, as well as
integrated infusion therapy and medication management solutions. Through its
products, Hospira helps improve the safety, cost and productivity of patient
care. The company is headquartered in Lake Forest, Ill., and has more than
14,000 employees. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 --
A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Hospira cautions that
these forward-looking statements are subject to risks and uncertainties that
may cause actual results to differ materially from those indicated in the
forward-looking statements. Economic, competitive, governmental, technological
and other factors that may affect Hospira's operations and may cause actual
results to be materially different from expectations include the risks,
uncertainties and factors discussed under the headings "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" in Hospira's latest Annual Report on Form 10-K, and Hospira's
subsequent Quarterly Reports on Form 10-Q, which are filed with the Securities
and Exchange Commission, and incorporated by reference. Hospira undertakes no
obligation to release publicly any revisions to forward-looking statements as
the result of subsequent events or developments.

(1) Institute of Medicine. Preventing Medication Errors. Washington, D.C.:
National Academy Press, 2007. 25 Jan. 2008 < http://www.nap.edu >
(2) Van den Berghe G, et al. N Engl J Med 2006;354:449-61.
(3) Krinsley JS, et al. Crit Care Med 2007;35:2262-7.

SOURCE Hospira, Inc.

Media, Tareta Adams, +1-224-212-2535, or Financial Community, Karen King,
+1-224-212-2711, both of Hospira, Inc.